Pacific Biosciences of California, Inc.
PACB
$1.38
$0.129.52%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 7.03% | -5.28% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 7.03% | -5.28% | |||
| Cost of Revenue | -17.39% | -3.94% | |||
| Gross Profit | 111.46% | -10.62% | |||
| SG&A Expenses | -9.94% | -28.32% | |||
| Depreciation & Amortization | -99.72% | 5,248.72% | |||
| Other Operating Expenses | -- | 307.62% | |||
| Total Operating Expenses | -81.99% | 265.31% | |||
| Operating Income | 89.64% | -384.06% | |||
| Income Before Tax | 90.17% | -15,968.14% | |||
| Income Tax Expenses | 111.59% | -195.57% | |||
| Earnings from Continuing Operations | 90.16% | -18,070.27% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 90.16% | -18,070.27% | |||
| EBIT | 89.64% | -384.06% | |||
| EBITDA | 32.66% | 23.30% | |||
| EPS Basic | 90.27% | -17,186.90% | |||
| Normalized Basic EPS | 90.41% | -360.07% | |||
| EPS Diluted | 90.28% | -17,660.98% | |||
| Normalized Diluted EPS | 90.41% | -398.96% | |||
| Average Basic Shares Outstanding | 1.11% | 4.90% | |||
| Average Diluted Shares Outstanding | 1.11% | -3.27% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||